trans-1-(4-fluorophenyl)-4-(5-fluoropyridin-2-yl)-4-phenoxycyclohexanecarbonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: trans-1-(4-fluorophenyl)-4-(5-fluoropyridin-2-yl)-4-phenoxycyclohexanecarbonitrile
• 英文别名: 1-(4-Fluorophenyl)-4-(5-fluoropyridin-2-yl)-4-phenoxycyclohexane-1-carbonitrile
• 化学式: C₂₄H₂₀F₂N₂O
• 分子量: 390.432
• InChiKey: CAAPDRXHWFXTLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  trans-1-(4-fluorophenyl)-4-(5-fluoropyridin-2-yl)-4-hydroxycyclohexanecarbonitrile 、 triphenylbismuth(V) diacetate 在 copper diacetate 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 trans-1-(4-fluorophenyl)-4-(5-fluoropyridin-2-yl)-4-phenoxycyclohexanecarbonitrile
  参考文献：
  名称：

  WO2008/148468

  摘要：

  公开号：

文献信息

• Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them
  申请人：BOHME Thomas

  公开号：US20100204206A1

  公开（公告）日：2010-08-12

  Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar 1 , Ar 2 , R 1 and R 2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

  本发明涉及式I的二(杂)芳基环己烷衍生物，其制备方法、其用途以及包含它们的制药组合物。其中，Ar1、Ar2、R1和R2的含义如权利要求所示。式I的化合物是有价值的药物活性化合物，可以抑制心肌中的ATP敏感性钾通道，并适用于治疗心血管系统的疾病，如心律失常或心脏收缩力下降，例如冠心病、心力衰竭或心肌病等。特别地，它们适用于预防突发性心脏死亡。本发明还涉及制备式I化合物的过程和中间体、它们的用途以及包含它们的制药组合物。
• DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
  申请人：SANOFI

  公开号：EP2164825B1

  公开（公告）日：2014-04-30
• US8076324B2
  申请人：——

  公开号：US8076324B2

  公开（公告）日：2011-12-13
• [EN] DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DÉRIVÉS DE DI(HÉTÉRO)ARYLCYCLOHEXANE, LEUR PRÉPARATION, LEUR UTILISATION ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：SANOFI AVENTIS

  公开号：WO2008148468A1

  公开（公告）日：2008-12-11

  [EN] The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.
  [FR] La présente invention porte sur des dérivés de di(hétéro)arylcyclohexane représentés par la formule (I), dans laquelle Ar1, Ar2, R1 et R2 ont les significations indiquées dans les revendications. Les composés de la formule (I) sont des composés pharmaceutiques actifs servant à inhiber les canaux potassiques sensibles à l'ATP dans le muscle cardiaque et sont appropriés, par exemple, pour le traitement de troubles du système cardiovasculaire tels que des arythmies ou une contractilité cardiaque diminuée qui se produisent, par exemple, lors d'une coronaropathie, d'une insuffisance cardiaque ou des cardiomyopathies. En particulier, les composés sont utiles dans la prévention d'une mort cardiaque subite. L'invention porte, de plus, sur des procédés et des intermédiaires servant à la préparation des composés de la formule (I), sur leur utilisation et sur des compositions pharmaceutiques les comprenant.